Detalles de la búsqueda
1.
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON Study.
Oncology
; 101(1): 22-31, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36195058
2.
Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer.
Future Oncol
; 19(23): 1593-1600, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37584156
3.
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Int J Clin Oncol
; 28(8): 1073-1081, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37209158
4.
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
BMC Cancer
; 22(1): 19, 2022 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34980029
5.
A multicentre retrospective study comparing site-specific treatment with empiric treatment for unfavourable subset of cancer of unknown primary site.
Jpn J Clin Oncol
; 52(12): 1416-1422, 2022 Dec 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36047806
6.
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
Int J Clin Oncol
; 27(9): 1450-1458, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35861943
7.
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Int J Clin Oncol
; 26(5): 941-950, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33483857
8.
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Cancer Sci
; 110(11): 3565-3572, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31520559
9.
Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer.
Cancer Sci
; 110(3): 1032-1043, 2019 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-30657223
10.
Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
Gastric Cancer
; 22(4): 817-827, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30515672
11.
First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.
Gastric Cancer
; 21(5): 792-801, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-29353332
12.
Correction to: A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study.
Int J Clin Oncol
; 26(5): 951-953, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33656656
13.
A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
Target Oncol
; 19(2): 181-190, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38427280
14.
A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer.
Sci Rep
; 14(1): 12422, 2024 05 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38816500
15.
Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer.
Cancers (Basel)
; 15(18)2023 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37760533
16.
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.
Cancer Med
; 12(14): 14988-14999, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37226421
17.
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Sci Rep
; 13(1): 8815, 2023 05 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-37258608
18.
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Anticancer Res
; 43(4): 1817-1826, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36974805
19.
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.
Sci Rep
; 13(1): 19399, 2023 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37938630
20.
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study).
J Geriatr Oncol
; 13(1): 82-87, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34215525